Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 6/20 | 0.40 |
| ▸ | THRB | P10828 | 4/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | BLM | P54132 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | GABRR3 | A8MPY1 | 1/20 | 0.39 |
| ▸ | GABRP | O00591 | 1/20 | 0.39 |
| ▸ | GABRD | O14764 | 1/20 | 0.39 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.39 |
| ▸ | GABBR2 | O75899 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.39 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Temefos SCHEMBL44105 | 0.78 | LMNA (0.53) | LMNATHRBALDH1A1SMN1; SMN2CYP3A4 | |
| Temefos SCHEMBL23303378 | 0.78 | LMNA (0.53) | LMNATHRBALDH1A1SMN1; SMN2CYP3A4 | |
| Temefos SCHEMBL8741692 | 0.77 | LMNA (0.51) | LMNATHRBALDH1A1SMN1; SMN2CYP3A4 | |
| Temefos SCHEMBL6388031 | 0.77 | LMNA (0.51) | LMNATHRBALDH1A1SMN1; SMN2CYP3A4 | |
| Temefos SCHEMBL9193178 | 0.76 | LMNA (0.54) | LMNATHRBALDH1A1SMN1; SMN2CYP3A4 | |
| Temefos SCHEMBL10455340 | 0.76 | LMNA (0.47) | LMNATHRBALDH1A1SMN1; SMN2CYP3A4 | |
| Temefos SCHEMBL9809762 | 0.75 | LMNA (0.42) | LMNATHRBALDH1A1SMN1; SMN2CYP3A4 | |
| Temefos SCHEMBL20840360 | 0.74 | LMNA (0.47) | LMNATHRBALDH1A1SMN1; SMN2CYP3A4 | |
| Temefos SCHEMBL9435846 | 0.70 | LMNA (0.40) | LMNATHRBALDH1A1SMN1; SMN2CYP3A4 | |
| Temefos SCHEMBL20919592 | 0.70 | ALDH1A1 (0.46) | LMNATHRBALDH1A1SMN1; SMN2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022150559-A1 | METHODS FOR TREATMENT OF CANCER USING ABL INHIBITORS AND DRUGS TARGETING THE MEVALONATE PATHWAY | DUKE UNIVERSITY (US) | 2022-07-14 | — | — | WO | disclosed |
| EP-3813949-A1 | ENERGETIC\" CANCER STEM CELLS (E-CSCS): A NEW HYPER-METABOLIC AND PROLIFERATIVE TUMOR CELL PHENOTYPE, DRIVEN BY MITOCHONDRIAL ENERGY | Lunella Biotech, Inc. (CA) | 2021-05-05 | — | — | EP | disclosed |
| EP-3695005-A1 | ANTI-MITOCHONDRIAL INHIBITORS FOR ONCOGENIC RAS AND MYC | Lunella Biotech, Inc. (CA) | 2020-08-19 | — | — | EP | disclosed |
| EP-3612187-A1 | VITAMIN C AND DOXYCYCLINE: A SYNTHETIC LETHAL COMBINATION THERAPY FOR ERADICATING CANCER STEM CELLS (CSCS) | Lunella Biotech, Inc. (CA) | 2020-02-26 | — | — | EP | disclosed |
| EP-3612177-A1 | TARGETING HYPOXIC CANCER STEM CELLS (CSCS) WITH DOXYCYCLINE: IMPLICATIONS FOR IMPROVING ANTI-ANGIOGENIC THERAPY | Lunella Biotech, Inc. (CA) | 2020-02-26 | — | — | EP | disclosed |
| EP-3490581-A2 | NEUROMODULATING COMPOSITIONS AND RELATED THERAPEUTIC METHODS FOR THE TREATMENT OF CANCER | Flagship Pioneering Innovations V, Inc. (US) | 2019-06-05 | — | — | EP | disclosed |
| WO-2019075219-A1 | ANTI-MITOCHONDRIAL INHIBITORS FOR ONCOGENIC RAS AND MYC | LUNELLA BIOTECH, INC. (CA) | 2019-04-18 | — | — | WO | disclosed |
| WO-2019075209-A1 | ANTI-MITOCHONDRIAL INHIBITORS FOR ONCOGENIC RAS AND MYC | LUNELLA BIOTECH, INC. (CA) | 2019-04-18 | — | — | WO | disclosed |
| WO-2019075226-A1 | ANTI-MITOCHONDRIAL INHIBITORS FOR ONCOGENIC RAS AND MYC | LUNELLA BIOTECH, INC. (CA) | 2019-04-18 | — | — | WO | disclosed |
| EP-3442706-A1 | SAMPLE COLLECTION AND PRESERVATION DEVICES, SYSTEMS AND METHODS | NextGen Jane, Inc. (US) | 2019-02-20 | — | — | EP | disclosed |
| WO-2012120301-A1 | EVALUATION OF THERAPEUTIC AGENT | DUNDEE CELL PRODUCTS LIMITED (GB) | 2012-09-13 | — | — | WO | disclosed |
| EP-2425021-A1 | INDEX OF GENOMIC EXPRESSION OF ESTROGEN RECEPTOR (ER) AND ER-RELATED GENES | Nuvera Biosciences, Inc. (US) | 2012-03-07 | — | — | EP | disclosed |
| WO-2011120984-A1 | METHOD FOR BREAST CANCER RECURRENCE PREDICTION UNDER ENDOCRINE TREATMENT | SIVIDON DIAGNOSTICS GMBH (DE) | 2011-10-06 | — | — | WO | disclosed |
| WO-2010127338-A1 | INDEX OF GENOMIC EXPRESSION OF ESTROGEN RECEPTOR (ER) AND ER-RELATED GENES | NUVERA BIOSCIENCES, INC. (US) | 2010-11-04 | — | — | WO | disclosed |
| EP-1880332-A2 | NOVEL METHODS AND DEVICES FOR EVALUATING POISONS | Emiliem (US) | 2008-01-23 | — | — | EP | disclosed |
| US-20070259363-A1 | Phylogenetic Analysis of Mass Spectrometry or Gene Array Data for the Diagnosis of Physiological Conditions | AMRI HAKIMA | 2007-11-08 | — | — | US | disclosed |
| WO-2006116622-A2 | NOVEL METHODS AND DEVICES FOR EVALUATING POISONS | EMILIEM (US) | 2006-11-02 | — | — | WO | disclosed |
| EP-1599607-A2 | SIGNATURES OF ER STATUS IN BREAST CANCER | Arcturus Bioscience, Inc. (US) | 2005-11-30 | — | — | EP | disclosed |
| US-20050208500-A1 | Signatures of ER status in breast cancer | ARCUTURUS BIOSCIENCE, INC. | 2005-09-22 | — | — | US | disclosed |
| WO-2004079014-A2 | SIGNATURES OF ER STATUS IN BREAST CANCER | ARCTURUS BIOSCIENCE, INC. (US) | 2004-09-16 | — | — | WO | disclosed |